Pesquisar
Sarepta Therapeutics Inc
SRPTAdicionar à lista de desejos
17.550USD
-1.130-6.05%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
1.84BValor de mercado
28.16P/L TTM
Mais detalhes de Sarepta Therapeutics Inc Empresa
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Informações de Sarepta Therapeutics Inc
Código da empresaSRPT
Nome da EmpresaSarepta Therapeutics Inc
Data de listagemJun 04, 1997
CEOIngram (Douglas S)
Número de funcionários1372
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 04
Endereço215 First Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16172744000
Sitehttps://www.sarepta.com/
Código da empresaSRPT
Data de listagemJun 04, 1997
CEOIngram (Douglas S)
Executivos da empresa Sarepta Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
25.22K
+9.45%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.52K
-1072.63%
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Stephen L. Mayo, Ph.D.
Dr. Stephen L. Mayo, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.70B
77.29%
Rest of World
165.18M
7.51%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Outro
63.85%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Outro
63.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.23%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
11.54%
Research Firm
6.41%
Individual Investor
4.09%
Pension Fund
1.88%
Bank and Trust
0.73%
Family Office
0.45%
Sovereign Wealth Fund
0.35%
Outro
4.54%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1037
95.57M
90.53%
-25.27M
2025Q4
1032
91.00M
86.84%
-18.75M
2025Q3
1019
84.30M
80.53%
-21.85M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
12.56M
11.96%
+1.03M
+8.96%
Dec 31, 2025
AQR Capital Management, LLC
7.80M
7.43%
+6.39M
+454.65%
Dec 31, 2025
State Street Investment Management (US)
6.60M
6.29%
+1.29M
+24.40%
Dec 31, 2025
Two Sigma Investments, LP
4.51M
4.3%
+416.99K
+10.18%
Dec 31, 2025
Barry (Richard J)
3.21M
3.06%
+32.60K
+1.02%
May 16, 2025
Erste Asset Management GmbH
2.73M
2.6%
+43.00K
+1.60%
Dec 31, 2025
abrdn Inc.
2.25M
2.14%
+268.83K
+13.56%
Dec 31, 2025
UBS Financial Services, Inc.
2.06M
1.96%
+82.28K
+4.16%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
3.74%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Invesco Biotechnology & Genome ETF
3.49%
Invesco S&P SmallCap Health Care ETF
1.44%
Global X Genomics & Biotechnology ETF
1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
1.32%
Virtus LifeSci Biotech Products ETF
1.03%
State Street SPDR S&P Biotech ETF
1.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Health Care Alphadex Fund
0.51%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção3.74%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.65%
Invesco Biotechnology & Genome ETF
Proporção3.49%
Invesco S&P SmallCap Health Care ETF
Proporção1.44%
Global X Genomics & Biotechnology ETF
Proporção1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.32%
Virtus LifeSci Biotech Products ETF
Proporção1.03%
State Street SPDR S&P Biotech ETF
Proporção1.03%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.63%
First Trust Health Care Alphadex Fund
Proporção0.51%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
